Anthula KAVO

En résumé

Entreprises

• Doctoral School of Sciences of Life SVS402-Universite Paris Est - Representative member of Phd students in the comity of Doctoral School of Sciences of Life SVS 402

  2013 - 2015 Establishment of a contact between phd students and Doctoral School
  Proposition of training session endorsing the link between PhD and -PhD students in Biomedical Industry
  Establishment of evaluation of the Doctoral School from the PhD students

• Université Paris-Est-Institut Mondor of Biomedical Research - Project Manager-Young Researcher

  2011 - 2015 Simultaneous managment of 3 scientific projects for the understanding of molecular and cellular bases of Neural Crest development (specific cell population with essential contribution during embryogenesis) and associated pathologies.
  Classic methods of molecular biology and ex vivo methods (cell cultures) were followed by the use of animal model (mouse) in order to validate our in vitro observations in a more reliable in vivo model.
  2 publications in distinguished scientific journals (Kavo et al., 2015, Lecerf et al., 2015) and one ongoing project contributing to the unserstanding of molecular basis of Neural Crest related pathologies, better clinical evaluation and improvement of patiens care.

• Laboratory of Metabolic Syndrome - Pharmacology-Toxicology Unit of Medical School, University of Pat - Young Researcher in Biomedical Sciences

  2009 - 2011 The ultimate goal of this 2 years project was the qualitative characteristics of HDL in young patients of an acute myocardial infarction. This study led us to report marked alterations in the ratio of plasma apoA-I concentration over plasma apoC-III concentration ([apoA-I]/[apoC-III] ratio), in the HDL subpopulation distribution and in the oxidation potential of HDL between the young patients and the control group.
  Such changes further validated by epidemiological studies may serve as markers for the early identification of young individuals at high risk for a life-threatening acute myocardial infarction.

• Laboratory of Molecular Physiology-Toxicology, School of Molecular Biology and Genetics, Democritus - Young Researcher in Biomedical Sciences

  2008 - 2009 During this one year undergraduate project, we focused on the role of antioxidants and in particular silibinin in cardiac hypertrophy. This plant flavonolignan with potent antioxidant activity, was evaluated in embryonic rat heart-derived for its effects in preventing hydrogen peroxide (H2O2)-induced cellular damage and blocking the phenylephrine-induced hypertrophic response.
  Based on our results, silibinin may attenuate the phenylephrine-induced hypertrophic response of heart-derived cells via antioxidant mechanisms involving mainly the inhibition of the intracellular signaling pathways mediated by ERK1/2 MAPKs and Akt.
  Proposed new promissing therapy in the treatment of myocardial hypertrophy.
  Results published in distinguished scientific journal as second author (Anestopoulos I et al., 2013)

Formations

• Université Paris-Est-Institut Mondor Of Biomedical Research

  Creteil 2012 - 2015 PhD

• Université Paris-Est-Institut Mondor Of Biomedical Research

  Creteil 2011 - 2012 Master 2

• Medical School, University Of Pat (Patras)

  Patras 2009 - 2011 Master 1-Master 2

• Democritus University Of Thrace (Thessaloniki/Xanthi/Kozani)

  Thessaloniki/Xanthi/Kozani 2005 - 2009 Diploma in Molecular Biology and Genetics